investigation and Comparison of the effect of Daflon and pentoxifylline in the treatment of patients with chronic venous insufficiency
Phase 1
Recruiting
- Conditions
- Patients with chronic venous insufficiency.Venous insufficiency (chronic) (peripheral)I87.2
- Registration Number
- IRCT20221213056808N1
- Lead Sponsor
- Gorgan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Chronic venous insufficiency disease with class C2 and more according to CEAP criteria
Consent to take medicine
Ability to communicate
Exclusion Criteria
Patients who are candidates for surgery
Patients who do not take medicine
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CEAP( classification stands for Clinical (C), Etiological (E), Anatomical (A), and Pathophysiological (P)) Score. Timepoint: At the beginning of the study and 6 months after taking the drug. Method of measurement: C0: no obvious features of the disease: C1: spider veins C2: obvious varicose veins: C3: edema: C4: eczema and skin discoloration: C5: healing wounds C6: active wounds with exudation.;Venous Clinical Severity Score(vcss score). Timepoint: At the beginning of the study and 6 months after taking the drug. Method of measurement: Pigmentation: 0-2 Vascularity: 0-5 Pliability: 0-5 Height: 0-3.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Daflon's venoactive effects in chronic venous insufficiency (CVI) compared to pentoxifylline's phosphodiesterase inhibition?
How does Daflon's efficacy in improving venous tone and microcirculation compare to pentoxifylline in IRCT20221213056808N1 Phase I trial for I87.2 patients?
Which biomarkers (e.g., inflammatory markers, endothelial function indicators) correlate with treatment response to Daflon or pentoxifylline in CVI clinical trials?
What are the potential adverse event profiles of Daflon versus pentoxifylline in Phase I studies for peripheral chronic venous insufficiency?
How do Daflon and pentoxifylline compare to other venoactive agents like escin or antithrombotic therapies in managing I87.2 chronic venous insufficiency?